Skip to content

Cystine Capacity Clinical Study (CysCap)

Cystine Capacity Clinical Study (CysCap)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02120105
Enrollment
30
Registered
2014-04-22
Start date
2012-09-30
Completion date
2017-02-24
Last updated
2018-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystinuria

Keywords

Renal aminoaciduria, cystinuria, D-penicillamine, renal tubular transport, inborn errors, tiopronin, urolithiasis

Brief summary

The purpose of this study is to determine whether urinary cystine capacity, an assay used to measure the amount of cystine in the urine, can be used to predict stone recurrence in patients with cystinuria.

Detailed description

Cystinuria is a rare genetic cause of kidney stones that leads to significant morbidity due to the recurrent nature of the disease. Despite recent advancements in knowledge about cystinuria, such as the discovery of the genetic defects that cause the disease, there have been very few studies of clinical determinants of recurrent stone formation. An optimal method of measuring cystine solubility in the urine has been lacking, and therefore response to pharmacologic and dietary therapy is often not known. Recently, a new assay to measure the amount of cystine in the urine was developed called Cystine Capacity, or CysCap. It is an assay that adds a pre-formed amount of cystine crystals to urine and measures the amount of cystine the urine can take up from the solid phase (in undersaturated urine) or gives up to solid phase (in supersaturated urine). This study seeks to examine how well this measure of urinary cystine predicts stone occurrence, with the ultimate goal of helping to guide therapy and preventing kidney stones in cystinurics. This is an observational study over 3 years. Subjects who are enrolled in the study will perform semi-annual 24-hour urine collections. They will undergo imaging of the kidneys every 6 months to monitor kidney stone formation or growth, in order to correlate urinary parameters with clinical events. The study will examine how well the urinary cystine capacity predicts stone formation.

Interventions

None listed

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
8 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients with a confirmed laboratory diagnosis of cystinuria will be included in this study. There will be no age barrier to inclusion, but included patients must be able to reliably collect urine for 24 hours. Men and women will be recruited equally and there are no restrictions for racial or ethnic origin in this study. * Patient enrollment will require signing of an informed consent document approved by the Lenox Hill IRB. * For children 8-18 years of age, signing an assent to participate will also be required.

Exclusion criteria

* Patients will be excluded if they cannot sign consent or assent. * Furthermore if the patient cannot reliably collect urine for 24 hours or adhere to study follow up visit requirements.

Design outcomes

Primary

MeasureTime frameDescription
Cystine capacity will be correlated with recurrence or non-recurrence of stonesevery 6 months over 3 yearsThe primary end point will be cystine capacity in participants who do and do not have recurrence of stones seen on radiologic imaging in the ipsilateral kidney which was rendered stone-free prior to enrollment. Subjects who are enrolled in the study will perform semi-annual 24-hour urine collections for measurement of cystine capacity. They will undergo imaging of the kidneys every 6 months to monitor kidney stone formation or growth, in order to correlate urinary parameters with clinical events.

Secondary

MeasureTime frameDescription
24-hour urine cystine excretionevery 6 months over 3 yearsWe will compare 24 hour urine cystine excretion in patients who remain stone free and those who experience stone recurrence.
episodes of renal colic and/or stone passage from a kidney that was previously stone-freeevery 6 months over 3 yearsAssessed by renal imaging, either ultrasound or CT scan, every 6 months.
Evidence of new asymptomatic stones noted on the contralateral kidneyevery 6 months over 3 year observational studyCystine capacity will be compared in participants with or without recurrence of stones in the contralateral kidney by renal ultrasound or CT scan

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026